AMGEN INC 8-K

What Happened
Amgen Inc. announced on February 3, 2026 (8‑K furnished) its unaudited results for the three months and full year ended December 31, 2025, and its unaudited financial position as of December 31, 2025. The company’s press release (Exhibit 99.1) includes both GAAP results and a range of non‑GAAP financial measures and reconciliations. The filing was signed by Peter H. Griffith, Executive VP and Chief Financial Officer.

Key Details

• Filing date: February 3, 2026; reporting period: three months and year ended December 31, 2025.
• Non‑GAAP measures disclosed: non‑GAAP EPS, non‑GAAP operating income and margin, non‑GAAP tax rate, non‑GAAP operating expenses and subcomponents (cost of sales, R&D, SG&A). Reconciliations to GAAP are included.
• Cash and leverage metrics: Free Cash Flow (FCF) defined as GAAP operating cash flow minus capital expenditures; EBITDA for FY2025 defined as GAAP net income plus interest, taxes, depreciation and amortization; debt leverage ratio = GAAP total debt / EBITDA.
• Adjustments excluded from non‑GAAP measures are detailed and include acquisition‑related charges (amortization/impairment of acquired intangible assets and inventory step‑up), restructuring and cost‑savings charges, certain investment gains/losses and legal items, and related tax impacts.

Why It Matters
Amgen’s inclusion of non‑GAAP metrics (with reconciliations) gives investors additional ways to evaluate underlying operating performance, liquidity (via FCF) and leverage (via EBITDA and debt ratio) for FY2025. Because the company uses these non‑GAAP measures internally for budgeting and incentives, they can help investors compare current results to past periods and management targets—but they are supplemental to, not a replacement for, GAAP figures. The press release is furnished as an exhibit (not “filed”), which is a technical disclosure note in the 8‑K.